Page last updated: 2024-11-06

neocuproine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Neocuproine, also known as 2,9-dimethyl-1,10-phenanthroline, is a chelating agent that forms stable complexes with copper(I) ions. Its synthesis involves a multi-step process starting with the condensation of o-phenylenediamine with 2,4-pentanedione. Neocuproine is widely studied for its high selectivity and sensitivity in spectrophotometric and fluorimetric determination of copper in various matrices, including biological samples, environmental samples, and industrial materials. The compound's ability to form a strongly colored complex with copper(I) allows for quantitative analysis. It plays a crucial role in developing analytical methods for copper detection, contributing to areas such as environmental monitoring, food safety, and clinical diagnostics.'

neocuproine: Spectrophotometric determination of copper and ultramicro blood sugar determinations; structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

neocuproine : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two methyl substituents at positions 2 and 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65237
CHEMBL ID375781
CHEBI ID91222
SCHEMBL ID124563
MeSH IDM0043411

Synonyms (67)

Synonym
ksc-09-264b
KUC107774N
2,9-dimethylphenanthroline
neocuproine
neo-cuproin
1, 2,9-dimethyl-
nsc-4280
nsc4280 ,
484-11-7
neocuproin
2,10-phenanthroline
2,9-dimethyl-o-phenanthroline
1,10-phenanthroline, 2,9-dimethyl-
NCI60_003986
NCIMECH_000034
2,9-dimethyl-1,10-phenanthroline
OPREA1_068014
EU-0036872
einecs 207-601-9
nsc 4280
MLS001194484 ,
smr000555011
neocuproine, >=98%
D0771
AKOS000511700
CHEMBL375781
dndi1343110
gnf-pf-5611 ,
NCGC00245843-01
unii-8e7d2sh3bv
8e7d2sh3bv ,
A827529
CCG-16034
HMS2230M06
CCG-35468
FT-0610770
HMS3373K19
dmphen
vuf-7738
neocuproine [mi]
2,9-neocuproine
AB00443806-12
AB00443806-10
SCHEMBL124563
CHEBI:91222
2,9-di-methyl-1,10-phenanthroline
DTXSID5060065
J-610070
bdbm64740
cid_65237
mfcd00004973
2,9-dimethyl-1,10-phenanthroline hemihydrate, 98%
mephen
F20419
neocuproine, vetec(tm) reagent grade, 98%
CS-W004563
BCP18357
Q409347
SY010909
AS-14894
BRD-K16598630-001-05-7
dmphen; nsc 4280; neocuproin; vuf 7738
3,6-dimethyl-4,5-diazaphenanthrene
2,9-dimethyl-1,10-phenanthroline neocuproine
EN300-196274
Z1224384937
HY-W004563

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Both neocuproine treatment and ATP7A deficiency reduced IFN-γ, MCP-1, MCP-3, and VEGF-A levels."( Production of LPS-induced inflammatory mediators in murine peritoneal macrophages: neocuproine as a broad inhibitor and ATP7A as a selective regulator.
Patel, OV; Qin, Z; Wilson, WB, 2013
)
1.07

Toxicity

ExcerptReferenceRelevance
"We previously determined that the dithiocarbamate pesticide sodium metam (NaM) and its active ingredient methylisothiocyanate (MITC) were developmentally toxic causing notochord distortions in the zebrafish."( Dithiocarbamates have a common toxic effect on zebrafish body axis formation.
Alzarban, N; La Du, JK; Tanguay, RL; Tilton, F; Vue, M, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Interestingly, a bimodal H2O2 dose-response relationship in cell toxicity has been reported for Escherichia coli deficient in DNA repair as well as Chinese hamster ovary (CHO) cells."( Micromolar concentrations of hydrogen peroxide induce oxidative DNA lesions more efficiently than millimolar concentrations in mammalian cells.
Nakamura, J; Purvis, ER; Swenberg, JA, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
copper chelatorA chelator that is any compound containing a ligand (typically organic) which is able to form a bond to a central copper atom at two or more points.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
phenanthrolines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ajmaline and sarpagine biosynthesis238

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency100.00000.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency35.48130.140911.194039.8107AID2451
glp-1 receptor, partialHomo sapiens (human)Potency0.50120.01846.806014.1254AID624417
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency0.08110.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency3.54810.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency15.84890.707912.194339.8107AID720542
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency10.00000.28189.721235.4813AID2326
IDH1Homo sapiens (human)Potency0.00580.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.73080.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency0.22390.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency0.63100.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.01410.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.01410.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.01410.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.40680.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency0.34820.004611.374133.4983AID624296; AID624297
VprHuman immunodeficiency virus 1Potency39.81071.584919.626463.0957AID651644
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
TAR DNA-binding protein 43Homo sapiens (human)Potency4.46681.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
C-C chemokine receptor type 1Homo sapiens (human)IC50 (µMol)1,000.00000.00070.20022.5000AID716289
C-C chemokine receptor type 5Homo sapiens (human)IC50 (µMol)30.81140.00020.25679.0000AID716287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein 90Candida albicansEC50 (µMol)100.33300.12006.485533.8530AID2387; AID2400; AID2423
calcineurin A1, putativeCandida dubliniensis CD36EC50 (µMol)180.00004.66306.38108.0990AID2388
C-C chemokine receptor type 1Homo sapiens (human)EC50 (µMol)1.59241.50002.98566.3096AID716296
C-C chemokine receptor type 5Homo sapiens (human)EC50 (µMol)65.04780.00702.09365.0119AID716295
C-C chemokine receptor type 8Homo sapiens (human)EC50 (µMol)1,000.00000.48003.72297.9433AID716294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (51)

Processvia Protein(s)Taxonomy
dendritic cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 1Homo sapiens (human)
exocytosisC-C chemokine receptor type 1Homo sapiens (human)
chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
immune responseC-C chemokine receptor type 1Homo sapiens (human)
cell adhesionC-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 1Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 1Homo sapiens (human)
response to woundingC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of gene expressionC-C chemokine receptor type 1Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cell migrationC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of bone mineralizationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of osteoclast differentiationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 1Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 1Homo sapiens (human)
MAPK cascadeC-C chemokine receptor type 5Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
cellular defense responseC-C chemokine receptor type 5Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 5Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulumC-C chemokine receptor type 5Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 5Homo sapiens (human)
signalingC-C chemokine receptor type 5Homo sapiens (human)
symbiont entry into host cellC-C chemokine receptor type 5Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 5Homo sapiens (human)
response to cholesterolC-C chemokine receptor type 5Homo sapiens (human)
cellular response to lipopolysaccharideC-C chemokine receptor type 5Homo sapiens (human)
negative regulation of macrophage apoptotic processC-C chemokine receptor type 5Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 5Homo sapiens (human)
immune responseC-C chemokine receptor type 5Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 5Homo sapiens (human)
chemotaxisC-C chemokine receptor type 8Homo sapiens (human)
cell adhesionC-C chemokine receptor type 8Homo sapiens (human)
G protein-coupled receptor signaling pathwayC-C chemokine receptor type 8Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 8Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 8Homo sapiens (human)
immune responseC-C chemokine receptor type 8Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 8Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 8Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 1Homo sapiens (human)
virus receptor activityC-C chemokine receptor type 5Homo sapiens (human)
actin bindingC-C chemokine receptor type 5Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
protein bindingC-C chemokine receptor type 5Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 5Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 5Homo sapiens (human)
identical protein bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 5Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 8Homo sapiens (human)
coreceptor activityC-C chemokine receptor type 8Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 8Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 8Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
cytoplasmC-C chemokine receptor type 1Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
endosomeC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cell surfaceC-C chemokine receptor type 5Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 5Homo sapiens (human)
cytoplasmC-C chemokine receptor type 5Homo sapiens (human)
plasma membraneC-C chemokine receptor type 8Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 8Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID716287Displacement of [125I]-CCL3 from human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID276763Cytotoxicity against mouse ScN2a cells up to 1 uM2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID716286Displacement of [125I]-CCL3 from human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716298Allosteric modulation at human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID716289Displacement of [125I]-CCL3 from human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr after 3 hrs2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID322956Inhibition of synthetic amyloid beta42 oligomer formation by Western blot2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID716293Binding affinity to Zn(II) after 2 hrs using FluoZin-3 by fuorescence assay2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID716300Ratio of ZnPhe EC50 to compound EC50 for human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID716294Allosteric modulation at human CCR8 transfected in COS7 cells assessed as [3H]IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID276761Inhibition of PrP-res formation in mouse ScN2a cells relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID716295Allosteric modulation at human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID276764Cytotoxicity against prion Fukuoka1 strain infected mouse N2a#58 cells up to 1uM2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID716296Allosteric modulation at human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as {3H]IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID276762Inhibition of PrP-res formation in prion Fukuoka1 strain infected mouse N2a#58 cells relative to control2006Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23
Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug.
AID716302Ratio of ZnPhe EC50 to compound EC50 for human CCR5 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as IP3 turnover by liquid scintillation counting analysis2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID716297Allosteric modulation at human CCR1 transfected in COS7 cells coexpressing chimeric Gqi4myr assessed as [3H]IP3 turnover by liquid scintillation counting analysis relative to basal level2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (163)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (10.43)18.7374
1990's27 (16.56)18.2507
2000's59 (36.20)29.6817
2010's48 (29.45)24.3611
2020's12 (7.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.82 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index60.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other166 (99.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]